Affimed (NASDAQ:AFMD) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Affimed (NASDAQ:AFMDGet Rating) from a sell rating to a hold rating in a report published on Monday morning.

AFMD has been the subject of several other research reports. Wells Fargo & Company reaffirmed an overweight rating on shares of Affimed in a report on Thursday, August 18th. Stifel Nicolaus downgraded Affimed from a buy rating to a hold rating and dropped their target price for the stock from $9.00 to $2.00 in a report on Monday, October 10th. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Affimed in a report on Wednesday, September 21st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $7.50.

Affimed Trading Up 6.4 %

Shares of Affimed stock opened at $2.16 on Monday. The business has a fifty day simple moving average of $1.96 and a two-hundred day simple moving average of $2.59. Affimed has a 1 year low of $1.40 and a 1 year high of $7.35. The company has a market capitalization of $266.59 million, a price-to-earnings ratio of -3.43 and a beta of 2.19. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.65 and a quick ratio of 5.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC raised its stake in Affimed by 8.9% in the third quarter. 683 Capital Management LLC now owns 8,350,000 shares of the biopharmaceutical company’s stock valued at $17,202,000 after purchasing an additional 685,000 shares in the last quarter. Woodline Partners LP acquired a new position in Affimed in the second quarter valued at about $6,953,000. State Street Corp raised its stake in Affimed by 5.0% in the third quarter. State Street Corp now owns 2,355,701 shares of the biopharmaceutical company’s stock valued at $4,853,000 after purchasing an additional 112,217 shares in the last quarter. Vanguard Group Inc. raised its stake in Affimed by 14.0% in the third quarter. Vanguard Group Inc. now owns 1,398,231 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 171,258 shares in the last quarter. Finally, Bain Capital Public Equity Management II LLC raised its stake in Affimed by 118.8% in the second quarter. Bain Capital Public Equity Management II LLC now owns 1,274,153 shares of the biopharmaceutical company’s stock valued at $3,529,000 after purchasing an additional 691,817 shares in the last quarter. Institutional investors and hedge funds own 71.08% of the company’s stock.

About Affimed

(Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.

Further Reading

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.